Follow Boston Scientific to never miss an important update.
Boston Scientific released 8 million dollars that had been held in escrow for Elutia, a company that develops drug-eluting materials for medical implants. This payment was a scheduled part of a previous agreement and was released on time without any claims or disputes. While this is a significant funding milestone for Elutia, it is a routine and minor transaction for Boston Scientific. It simply confirms that the terms of their partnership are being met as planned.
Source: GlobeNewsWire
Wells Fargo lowered its price target for the medical device maker from $50 to $48. This is the second time in a week an analyst has adjusted their expectations, following a similar move by Oppenheimer. Even with these lower targets, the average analyst expectation of $65 remains well above where the stock trades today.
Source: Wells Fargo
Oppenheimer analysts lowered their price target for the medical device maker from $85 to $65 while keeping their Outperform rating. This rating means the firm still expects the stock to do better than the broader market over the next year. The new $65 target is in line with the average across other Wall Street firms. While the lower target reflects a more cautious view on the stock's price, it still sits well above the current trading price of about $45. This suggests the firm still sees plenty of room for the stock to rise as the company continues to grow its heart and surgery device businesses.
Source: Oppenheimer
Arthur C. Butcher informed the company on September 21 that he will retire from his role as Executive Vice President and Group President for the MedSurg and Asia Pacific divisions. He has been a key leader for these segments, which include tools for endoscopy and urology.
He will stay on as a senior advisor until February 26, 2027, to help with the transition. While he leads a major part of the business, the long notice period and advisory role suggest an orderly handoff rather than a sudden shift in strategy.
Source: 8-K filing
Citigroup analysts lowered their rating on Boston Scientific from a buy to a neutral on Thursday. This change comes as the company manages the impact of a cyberattack that recently disrupted its manufacturing and shipping operations. While those systems have begun returning to normal, the firm is signaling a more cautious stance on the stock's near-term recovery.
Even with this downgrade, the average price target among analysts remains around $66, which is well above the current price of roughly $44. For long-term owners, the core question is how quickly the company can regain its momentum in high-growth areas like heart valve repair now that its factories are running again.
Management sets a beatable bar and clears it every time, having topped expectations for eight straight quarters. This track record suggests the business is predictable and leadership has a firm grip on its numbers.
| Expectation | |
|---|---|
| EPS | $0.77 |
| Revenue | $5.13B |
Follow Boston Scientific to get the latest and most important updates.
Follow BSX